Condition

Advanced Solid Tumors (1)

Breast Cancer (1)

Elderly (1)

Epithelial Ovarian Cancer (1)

Lymphomas (1)

Ovarian Cancer (1)

Ovarian Neoplasms (1)

Solid Tumors (1)

Overall Status

Completed (2)

Terminated (2)

Recruiting (1)

Withdrawn (1)

Phase

phase 1 (2)

phase 2 (2)

phase 3 (2)

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1)

Ludwig Institute for Cancer Research (1)

North Eastern German Society of Gynaecological Oncology (1)

Swiss Group for Clinical Cancer Research (1)

Universitaire Ziekenhuizen Leuven (1)

Xian-Janssen Pharmaceutical Ltd. (1)

Collaborator

ALZA (1)

Johns Hopkins University (1)

Sequus Pharmaceuticals (1)

Intervention

caelyx (6)

endoxan (1)

liposomal doxorubicin (1)

paclitaxel hcl (1)

recombinant human tnf-α (1)

tld-1 (1)

topotecan hcl (1)

Study Documents

Intervention Type

drug (6)

Funder Type

Other (4)

Industry (2)

Study Type

Interventional (6)

caelyx

Showing 1 - 6 of 6

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Advanced Solid Tumors Trial in Switzerland (TLD-1, Caelyx)

Recruiting

Advanced Solid Tumors

TLD-1
Caelyx

Bellinzona, Switzerland
+3 more

Dec 24, 2021

Ovarian Cancer Trial (Caelyx)

Completed

Ovarian Cancer

Caelyx

(no location specified)

Mar 24, 2016

Epithelial Ovarian Cancer Trial in China (CAELYX, Topotecan HCl)

Terminated

Has Results

Epithelial Ovarian Cancer

CAELYX
Topotecan HCl

Beijing, China
+6 more

Nov 17, 2015

Solid Tumors, Lymphomas Trial in Frankfurt (Recombinant human TNF-a, Liposomal doxorubicin, Caelyx)

Withdrawn

Solid Tumors
Lymphomas

Recombinant human TNF-α
+2 more

Frankfurt, Germany

Krankenhaus Nordwest

Jun 15, 2015

Breast Cancer, Elderly Trial in Gent, Leuven (Caelyx, endoxan)

Completed

Breast Cancer
Elderly

Caelyx
endoxan

Gent, Belgium
+1 more

Dec 8, 2014

Ovarian Tumors Trial (CAELYX, Paclitaxel HCl)

Terminated

Ovarian Neoplasms

CAELYX
Paclitaxel HCl

(no location specified)

Apr 23, 2010